Literature DB >> 31552603

Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews.

Emanuel Raschi1, Matteo Bianchin2, Milo Gatti2, Alessandro Squizzato3, Fabrizio De Ponti2.   

Abstract

Direct oral anticoagulants are now recommended by major guidelines as first-choice agents for both stroke prevention in non-valvular atrial fibrillation and treatment/prevention of venous thromboembolism in non-cancer patients. Although there are no published head-to-head trials comparing different direct oral anticoagulants, a growing body of evidence from indirect comparisons and observational studies is suggesting that each direct oral anticoagulant may have a specific risk profile. This review aims to (1) synthesize and critically assess the latest evidence in comparative effectiveness and safety research in the aforementioned consolidated therapeutic uses, by performing an overview of systematic reviews and (2) highlight current challenges, namely underexplored areas, where research should be directed, also considering ongoing unpublished studies. The evidence gathered so far on the risk-benefit profile of direct oral anticoagulants is appraised in the light of existing guidelines to discuss whether further implementation should be proposed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31552603     DOI: 10.1007/s40264-019-00866-7

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  85 in total

1.  Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation.

Authors:  Christina Ji-Young Lee; Thomas Alexander Gerds; Nicholas Carlson; Anders Nissen Bonde; Gunnar Hilmar Gislason; Morten Lamberts; Jonas Bjerring Olesen; Jannik Langtved Pallisgaard; Morten Lock Hansen; Christian Torp-Pedersen
Journal:  J Am Coll Cardiol       Date:  2018-07-03       Impact factor: 24.094

2.  Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.

Authors:  Guillermo Prada-Ramallal; Bahi Takkouche; Adolfo Figueiras
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

3.  Approaches to Direct Oral Anticoagulant Selection in Practice.

Authors:  Bridget Paravattil; Hazem Elewa
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-08-09       Impact factor: 2.457

4.  Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies.

Authors:  An-Hua Wei; Zhi-Chun Gu; Chi Zhang; Yu-Feng Ding; Dong Liu; Juan Li; Xiao-Yan Liu; Hou-Wen Lin; Jun Pu
Journal:  Int J Cardiol       Date:  2018-05-18       Impact factor: 4.164

5.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Jan Steffel; Peter Verhamme; Tatjana S Potpara; Pierre Albaladejo; Matthias Antz; Lien Desteghe; Karl Georg Haeusler; Jonas Oldgren; Holger Reinecke; Vanessa Roldan-Schilling; Nigel Rowell; Peter Sinnaeve; Ronan Collins; A John Camm; Hein Heidbüchel
Journal:  Eur Heart J       Date:  2018-04-21       Impact factor: 29.983

Review 6.  Disease risk score as a confounder summary method: systematic review and recommendations.

Authors:  Mina Tadrous; Joshua J Gagne; Til Stürmer; Suzanne M Cadarette
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-11-21       Impact factor: 2.890

Review 7.  Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs).

Authors:  Paolo Gelosa; Laura Castiglioni; Marco Tenconi; Ludovico Baldessin; Giorgio Racagni; Alberto Corsini; Stefano Bellosta
Journal:  Pharmacol Res       Date:  2018-07-21       Impact factor: 7.658

8.  Overadjustment bias and unnecessary adjustment in epidemiologic studies.

Authors:  Enrique F Schisterman; Stephen R Cole; Robert W Platt
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

9.  Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.

Authors:  Géric Maura; Antoine Pariente; François Alla; Cécile Billionnet
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-28       Impact factor: 2.890

Review 10.  Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.

Authors:  Emanuel Raschi; Matteo Bianchin; Walter Ageno; Roberto De Ponti; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

View more
  2 in total

Review 1.  The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.

Authors:  Milo Gatti; Emanuel Raschi; Elisabetta Poluzzi; Cristian Martignani; Stefania Salvagni; Andrea Ardizzoni; Igor Diemberger
Journal:  Curr Heart Fail Rep       Date:  2020-12

2.  Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.

Authors:  Marta Bellesini; Matteo Bianchin; Chiara Corradi; Marco Paolo Donadini; Emanuel Raschi; Alessandro Squizzato
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.